Quell Therapeutics Achieves Milestone for Type 1 Diabetes CAR-Treg Cell Therapy Program
Achievement of first significant research milestone triggers an option exercise payment of $10 million from AstraZeneca AstraZeneca will progress preclinical and clinical development of the selected lead T1D candidate Quell